Sanofi India Limited’s board meeting commenced at 2:30 p.m. and concluded at 4:45 p.m. on October 29, 2026. The meeting focused on strategic initiatives and operational updates, underscoring the company’s commitment to innovation and growth in the pharmaceutical sector.

Strategic Initiatives

The board deliberated on several strategic initiatives aimed at expanding market reach and enhancing product portfolios. Notably, the meeting highlighted plans to strengthen partnerships in the cardiovascular and diabetes segments, which are pivotal to the company’s growth strategy.

Operational Updates

The meeting also provided updates on operational efficiencies and cost management. The board reviewed measures taken to improve gross margins and operational efficiencies, which have contributed to the company’s robust financial performance.

Future Outlook

As a result of these strategic discussions and operational reviews, Sanofi India Limited is poised to continue its momentum in the pharmaceutical industry, focusing on sustainable long-term value creation and market leadership.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sanofi India Limited

Sanofi India Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

Sanofi falls 13.8% over three months and has not found a floor yet. D/E of 0.00 and a 4.16% dividend yield give the balance sheet a decent cushion. The 4.16% dividend yield is about the only thing keeping income investors interested right now. The stock sits at 2% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at -12.6% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Sanofi India Limited.

Strides Pharma Science Limited (STAR) announced its consolidated financial results for the quarter (Q2FY27) and half year (H1FY27) ended 30 September 2026, showcasing a strong performance. The company reported a revenue of ₹14,297 million, marking a 17% year-on-year growth, driven by a robust 31% YoY increase in the Ex-US Markets. The US business also saw a 9% YoY growth to ₹6,855 million. EBITDA rose to ₹2,509 million, crossing the ₹2,500 million mark for the first time, despite higher input material and freight costs.

Financial Highlights

The company’s operational PAT increased by 11.5% YoY to ₹1,358 million, while the reported PAT rose 2% YoY to ₹1,341 million. The operational EPS stood at ₹14.7, up from ₹13.2. The company’s diversification strategy is evident as the Ex-US Markets surpassed the US business in quarterly revenue for the first time. The company remains focused on mitigating cost pressures through continuous optimization initiatives.

Looking Ahead

Despite the dynamic external environment, Strides Pharma Science Limited is committed to delivering sustainable and profitable growth. The company expects the Net Debt to EBITDA ratio to stabilize by the end of the year. With new board member Mr. Biren Gabhawala, the company aims to strengthen its governance and oversight mechanisms.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Strides Pharma Science Limited

Strides Pharma Science Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Strides moves sideways over three months, with neither buyers nor sellers taking control. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. No meaningful dividend — total return is entirely dependent on capital appreciation. Buyers show up with 1.6x the volume of sellers. Moreover, they dominated on 16 of recent sessions versus 14 for sellers — a healthy accumulation pattern. The stock rises -2.8% in three months on 8.7% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Strides Pharma Science Limited.

Thyrocare Technologies Limited (hereinafter referred to as “Thyrocare”) (NSE: THYROCARE, BSE: 539871), a leading healthcare diagnostic company, today announced its results for the quarter ended September 30, 2026. Thyrocare reported consolidated revenue of INR 270.8 Cr in Q2FY27, up 25.1% year-on-year, driven primarily by a 26.7% increase in the Pathology segment.

Key Financial Highlights

Consolidated revenue registered a 25.1% year-on-year growth, driven primarily by a 26.7% increase in the Pathology segment. The exceptional item represents a one-time, non-cash impairment charge of Rs 45 Cr relating to NHL in consolidated books, recognised in connection with the definitive term sheet for the sale of the NHL business. This charge does not impact the Company’s operational performance.

Operational Performance

Thyrocare processed 61.6 million tests in Q2FY27, marking a strong 27.4% year-on-year growth and reinforcing its volume leadership position in the industry. The Pathology business maintained strong traction, with franchise revenue up 26.9% and partnership revenue up 27.9% year-on-year. Thyrocare’s commitment to quality continued to deliver Six Sigma-level performance, with complaints reduced to 2.9 per million (down 24% YoY) and an average turnaround time (ATAT) of 3.49 hours from sample receipt.

Future Outlook

Thyrocare continued its expansion into specialty diagnostics, marking the next phase of its growth journey. Having commenced with allergy and genomics, the Company is progressively expanding its specialty test portfolio, with a focus on building clinical trust through scientific rigour, uncompromising quality, and industry-leading turnaround times.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Thyrocare Technologies Limited

Thyrocare Technologies Limited belongs to the Healthcare › Diagnostics & Research sector. Here’s a quick read on where the business and the stock stand today.

Thyrocare gains 42.8% over three months and trades near its 52-week highs. The business compounds revenue at 16.7% and profits at 36.2% CAGR. That is strong double-digit growth on both counts. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock trades at 87% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Both the business and the stock move in the right direction. Revenue grows at 16.7%, profits at 36.2%, and the PEG sits at 1.41 — below its growth rate. That combination is rare. Check Fundamentals of Thyrocare Technologies Limited.